Premium
Effect of granulocyte colony‐stimulating factor on IL‐12 p40 production during chemotherapy for B‐cell lineage non‐Hodgkin's lymphoma patients
Author(s) -
Toubai Tomomi,
Tanaka Junji,
Ota Shuichi,
Fukuhara Takashi,
Hashino Satoshi,
Kondo Takeshi,
Shono Yusuke,
Morioka Masanobu,
Kawamura Tsugumichi,
Masauzi Nobuo,
Kakinoki Yasutaka,
Kobayashi Hajime,
Kunieda Yasuyuki,
Kasai Masaharu,
Kurosawa Mitsutoshi,
Asaka Masahiro,
Imamura Masahiro
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2006.00746.x
Subject(s) - granulocyte colony stimulating factor , chemotherapy , medicine , lymphoma , chop , cytokine , immune system , immunology , gastroenterology
Interleukin (IL)‐12 is a 70‐kDa cytokine comprised of two disulfide‐linked proteins (p35 and p40) and is essential for the initiation of effective immune response. Granulocyte‐colony stimulating factor (G‐CSF) affects the balance in the production of anti‐inflammatory cytokines. We investigated the serum IL‐12 p40 and IL‐12 Mix (p40 and p70) production in 28 patients with B‐cell lineage non‐Hodgkin's lymphoma (NHL) treated with chemotherapy (e.g., CHOP regimen) with or without G‐CSF administration and eight healthy volunteers. We found that serum levels of IL‐12 p40 (191.2 ± 150.0 pg/mL) and IL‐12 Mix (277.4 ± 274.5 pg/mL) in the patients before chemotherapy were higher than those in the healthy volunteers (IL‐12 p40: 76.4 ± 25.3 pg/mL, IL‐12 Mix: 48.5 ± 33.4 pg/mL) ( P = 0.04 and 0.02, respectively). Next, we examined the serum IL‐12 p40 and IL‐12 Mix levels in nine patients receiving chemotherapy with administration of G‐CSF (CG group, n = 9) and without G‐CSF (C group, n = 9). Serum IL‐12 p40 and IL‐12 Mix levels were decreased on 10 d after chemotherapy in both groups, and those in CG groups were significantly lower than those in C group. These results indicated that administration of G‐CSF decreased serum IL‐12 p40 and IL‐12 Mix levels. Overall survival (OS) at 24 months was not significantly different in the two groups (58.3% in group C vs. 80.0% in group CG, P = 0.67). However, the survival rate of patients at clinical stages III and IV in CG group ( n = 6, 66.0%) was significantly better than that of patients in C group ( n = 4, 25.0%) ( P = 0.02). Long‐term administration of G‐CSF appears to influence the survival rate by reducing immunosuppressive IL‐12 p40 production.